LinKinVax operates as a clinical-stage biotechnology company.
LinKinVax has raised $7.8M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
LinKinVax's investors include IQT, Jean-Paul Kress, Geoffrey Duyk, Alain Tingaud, Giorgio Anania.
LinKinVax is headquartered in Paris, France.
LinKinVax operates as a clinical-stage biotechnology company.
LinKinVax is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LinKinVax — Funding & Investors." VCBacked, January 9, 2023, https://www.vcbacked.co/company/linkinvax. Accessed August 14, 2026.
VCBacked. (2023). LinKinVax — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/linkinvax
{{cite web |title=LinKinVax — Funding & Investors |url=https://www.vcbacked.co/company/linkinvax |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated